What are the benefits or constraints to go to a corporate venture tool? Is it better to go with a pharma player that wants to be a limited partner in existing funds rather than corporate ventures? AS both have fundamentally different missions, what are the validating and limitation effects of working with a corporate VC? How to balance these two effects?
| Speakers |
|---|
|
Isaac Haq - ArchiMed Group |
|
Cheryl Zimberlin - M VENTURES |
|
Lionel Carnot - EARLYBIRD |
|
Joachim Vogt - AbbVie |
|
Pierre D’Epenoux - Imcheck Therapeutics |
